How big is Clearside Biomedical, Inc.?

As of Jun 18, Clearside Biomedical, Inc. has a market capitalization of 61.39 million, with net sales of 3.77 million and a net profit of -30.81 million over the last four quarters. The company's shareholder's funds are -38.85 million, and total assets are 25.13 million.

Market Cap: As of Jun 18, Clearside Biomedical, Inc. has a market capitalization of 61.39 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Clearside Biomedical reported net sales of 3.77 million and a net profit of -30.81 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -38.85 million, while total assets were reported at 25.13 million.

What does Clearside Biomedical, Inc. do?

Clearside Biomedical, Inc. is a clinical biopharmaceutical company focused on developing innovative therapies for blinding eye diseases. As of March 2025, it reported net sales of $2 million and a net loss of $8 million, with a market cap of $61.39 million.

Overview:<BR>Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 61.39 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.88 <BR>Return on Equity: 67.11% <BR>Price to Book: -1.34<BR><BR>Contact Details:<BR>Address: 900 N Point Pkwy Ste 200, ALPHARETTA GA: 30005-8995 <BR>Tel: ['1 678 2703631', '1 678 4308206'] <BR>Fax: 1 678 2704033 <BR>Website: http://clearsidebio.com/

Should I buy, sell or hold Clearside Biomedical, Inc.?

Who are in the management team of Clearside Biomedical, Inc.?

As of March 2022, the management team of Clearside Biomedical, Inc. includes Dr. Christy Shaffer as the Independent Chairman and Dr. George Lasezkay as the President and CEO, along with several Independent Directors on the Board.

As of March 2022, the management team of Clearside Biomedical, Inc. includes:<BR><BR>- Dr. Christy Shaffer, who serves as the Independent Chairman of the Board.<BR>- Dr. George Lasezkay, who is the President, Chief Executive Officer, and a Director.<BR><BR>Additionally, the Board of Directors comprises several Independent Directors, including Mr. Richard Croarkin, Mr. Jeffrey Edwards, Mr. William Humphries, Dr. Nancy Hutson, and Mr. Clay Thorp.

Is Clearside Biomedical, Inc. overvalued or undervalued?

As of August 14, 2023, Clearside Biomedical, Inc. is rated as risky and overvalued due to negative valuation ratios, despite a recent stock price surge of 1012.70%, indicating that investors should exercise caution.

As of 14 August 2023, the valuation grade for Clearside Biomedical, Inc. has moved from does not qualify to risky. The company is considered overvalued based on its negative valuation ratios, including a Price to Book Value of -1.33, an EV to EBIT of -3.91, and an EV to EBITDA of -3.96. In comparison to peers, Kinnate Biopharma, Inc. has a fair valuation with a P/E of -1.1313, while Veru, Inc. is also rated risky with an EV to EBITDA of -1.1714.<BR><BR>Despite the recent surge in stock price, with a 1-week return of 1012.70% compared to the S&P 500's 1.05%, the overall financial metrics indicate that Clearside Biomedical, Inc. is not positioned favorably within its industry. The combination of negative ratios and a risky valuation grade suggests that investors should approach this stock with caution.

Is Clearside Biomedical, Inc. technically bullish or bearish?

As of August 18, 2025, Clearside Biomedical, Inc. is in a bearish trend with weak strength, indicated by mildly bearish daily moving averages and bearish weekly RSI, despite recent short-term outperformance against the S&P 500.

As of 18 August 2025, the technical trend for Clearside Biomedical, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages being mildly bearish and the weekly RSI being bearish. Although the MACD and Bollinger Bands are bullish on both weekly and monthly time frames, the overall bearish trend is reinforced by the bearish RSI readings. The stock has significantly outperformed the S&P 500 over the past week and month, but longer-term returns show underperformance, particularly over the 3-year and 5-year periods.